Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is ... Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.33 | -1.12436115843 | 29.35 | 33.53 | 28.7 | 6990056 | 31.10940938 | CS |
| 4 | 7.55 | 35.1653469958 | 21.47 | 34.39 | 19.4275 | 7014757 | 29.9408344 | CS |
| 12 | 8.97 | 44.7381546135 | 20.05 | 34.39 | 19.342 | 4329324 | 26.74448189 | CS |
| 26 | 20.17 | 227.90960452 | 8.85 | 34.39 | 8.66 | 3798743 | 21.13894826 | CS |
| 52 | 23.49 | 424.773960217 | 5.53 | 34.39 | 5.34 | 3184776 | 15.68478004 | CS |
| 156 | 25.72 | 779.393939394 | 3.3 | 34.39 | 1.03 | 1952494 | 11.27682788 | CS |
| 260 | 19.41 | 201.97710718 | 9.61 | 34.39 | 1.03 | 1286255 | 10.97828442 | CS |
ollik78
1年前
makinezmoney
1年前
makinezmoney
1年前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。